A double blind trial of naloxone in the treatment of acute stroke.
Naloxone has been reported to have potential benefit in the treatment of stroke. We evaluated the effect of naloxone in a double-blind trial conducted with 15 stroke patients whose deficits ranged from 8 to 60 hours in duration. All but one patient sustained a cerebral infarction. Neurologic function was assessed before and five minutes after each of two injections given to each patient in a double-blind fashion. The injections consisted of naloxone (0.4 mg in 3 patients and 4.0 mg in 12 patients) and saline. Prior to the trial, samples of plasma were obtained for determination of immunoreactive beta-endorphin for each patient. Four patients showed minimal improvement following injection of naloxone, while five patients exhibited a slightly greater improvement following saline injection. There were no significant elevations of plasma beta-endorphin among stroke patients. We conclude that naloxone may not have a significant therapeutic role for stroke in the clinical setting.
D000208:Acute Disease; D000941:Antigens / Q000032:analysis; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004723:Endorphins / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D001615:beta-Endorphin
D000941:Antigens; D004723:Endorphins; D009270:Naloxone; D001615:beta-Endorphin